Prostate Cancer Treatment Platform
Our Mission
At Prostate Theranostics (PTX), we are dedicated to improving the lives of patients with advanced prostate cancer through the development of prostate-specific membrane antigen (PSMA)-targeted diagnostic and therapeutic technologies. If you have any questions about how our health matters to you, feel free to contact us.
Our Vision
The Power of PSMA-Targeted Theranostics
We are building a next-generation platform of PSMA-targeted small-molecule drug conjugates (SMDCs) — a concept inspired by the groundbreaking research of our founder, Dr. Alan Kozikowski, a leading medicinal chemist whose discoveries helped enable today’s PSMA-based imaging and therapeutic radiopharmaceuticals. If you have any questions about our innovative approach and how it relates to health matters, feel free to contact us.
Our Platform
Leaders in Medicinal Chemistry and Oncology, Prostate Theranostic’s SMDC technology combines the targeting power of our proprietary urea-based PSMA ligand with carefully chosen therapeutic payloads designed to kill cancer cells selectively. For inquiries related to our innovative approaches in health matters, please feel free to contact us.